IL312361A - Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses - Google Patents

Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses

Info

Publication number
IL312361A
IL312361A IL312361A IL31236124A IL312361A IL 312361 A IL312361 A IL 312361A IL 312361 A IL312361 A IL 312361A IL 31236124 A IL31236124 A IL 31236124A IL 312361 A IL312361 A IL 312361A
Authority
IL
Israel
Prior art keywords
therapeutic uses
hematopoietic progenitor
progenitor kinase
degraders
bifunctional
Prior art date
Application number
IL312361A
Other languages
English (en)
Hebrew (he)
Inventor
John Buell
Frederick Cohen
Ryan Pemberton
Hunter P Shunatona
Lan Wang
Mark Edward Zak
Original Assignee
Gilead Sciences Inc
Nurix Therapeutics Inc
John Buell
Frederick Cohen
Ryan Pemberton
Hunter P Shunatona
Lan Wang
Mark Edward Zak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Nurix Therapeutics Inc, John Buell, Frederick Cohen, Ryan Pemberton, Hunter P Shunatona, Lan Wang, Mark Edward Zak filed Critical Gilead Sciences Inc
Publication of IL312361A publication Critical patent/IL312361A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
IL312361A 2021-11-10 2022-11-09 Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses IL312361A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
PCT/US2022/049426 WO2023086399A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
IL312361A true IL312361A (en) 2024-06-01

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312361A IL312361A (en) 2021-11-10 2022-11-09 Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses

Country Status (12)

Country Link
US (2) US12091426B2 (https=)
EP (1) EP4430052A1 (https=)
JP (1) JP2024543377A (https=)
KR (1) KR20240101654A (https=)
CN (1) CN118510786A (https=)
AR (1) AR127625A1 (https=)
AU (1) AU2022388571A1 (https=)
CA (1) CA3235913A1 (https=)
IL (1) IL312361A (https=)
MX (1) MX2024005431A (https=)
TW (1) TW202334170A (https=)
WO (1) WO2023086399A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP7472103B2 (ja) 2018-08-22 2024-04-22 クルゲン(シャンハイ),インク. トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法
WO2020092528A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Hpk1の分解剤としてのヘテロ二官能性化合物
WO2021168197A1 (en) 2020-02-19 2021-08-26 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
US11739101B2 (en) * 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Also Published As

Publication number Publication date
JP2024543377A (ja) 2024-11-21
KR20240101654A (ko) 2024-07-02
CN118510786A (zh) 2024-08-16
WO2023086399A1 (en) 2023-05-19
US20240018162A1 (en) 2024-01-18
MX2024005431A (es) 2024-07-19
AU2022388571A1 (en) 2024-05-09
CA3235913A1 (en) 2023-05-19
US12091426B2 (en) 2024-09-17
TW202334170A (zh) 2023-09-01
US20240400587A1 (en) 2024-12-05
AR127625A1 (es) 2024-02-14
EP4430052A1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
IL312361A (en) Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses
HUE070709T2 (hu) Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk
IL285285A (en) Pairs of il-2 and their uses
IL287192A (en) Oligomeric polypeptides modulate t cells and methods for their use
SG11202005147WA (en) Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
ZA202001442B (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
CA3292080A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
ZA202207188B (en) Liquid tasimelteon formulations and methods of use thereof
GB202019475D0 (en) Therapeutic compounds and their use
GB202108572D0 (en) Therapeutic compounds and their use
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
IL310096A (en) CD38 modulators and methods of using them
PL3897188T3 (pl) Algowy składnik pasz do kontroli skutków kokcydiozy i nekrotycznego zapalenia jelit u drobiu
IL291543A (en) Medical preparations and their use
GB201909573D0 (en) Modulation of T cell cytotoxicity and related therapy
IL316562A (en) High-dose and convenient formulations of endoxifen
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
HK40116638A (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
IL311999A (en) New modulators of EHMT1 and EHMT2 and their therapeutic use
HK40089173A (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
IL263976A (en) Preparations containing memantin and melatonin
GB2583325B (en) Portable devices for administration of therapeutic gas mixtures and methods of use
IL290427A (en) Objects and methods for administering medical agents
GB2622725B (en) Modular platform and methods of assembly and use
IL312428A (en) Use of Maribavir for treatment and their treatment methods